News

News 11.09.2023 Zurich, Switzerland – September 7, 2023 InSphero today announced that the company is making their 3D in vitro products available to researchers in the European Union market more easily by signing a distribution agreement with Darwin Microfluidics, an innovative startup dedicated to bringing advanced microfluidic solutions to researchers worldwide. InSphero, a global pioneer in 3D cell...

News 25.08.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biopharmaceutical company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited...

News 09.08.2023 Schlieren (Zurich), Switzerland, August 9, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today reported a 148% growth in MagnetOs direct sales in the first six months of 2023. The enrollment of patients in the Phase II spine study for Fibrin-PTH was...

News 24.07.2023 Schlieren (Zurich), 20 July 2023 - LimmaTech Biologics AG (“LimmaTech Bio”), a clinicalstage biotech company developing vaccines for the prevention of life-threatening diseases, signed an in-license agreement with GlaxoSmithKline Biologicals SA (LSE/NYSE: GSK) enabling LimmaTech Bio to further develop and commercialize a quadrivalent bioconjugate vaccine candidate for shigellosis that GSK...

News 14.07.2023 Schlieren (Zurich), Switzerland, July 13, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the completion of enrollment in the STRUCTURE trial, which is investigating the safety and efficacy of Fibrin-PTH (KUR-113) in single-level transforaminal lumbar interbody fusion (TLIF) procedures in...